Feinberg School of Medicine Department of Surgery

Northwestern University Feinberg School of Medicine

Eczema

Esophagitis

Idiopathic Hypersomnia

Disorders of Excessive Somnolence

Sleepiness

Dermatitis

Eosinophilic Esophagitis

Atopic Dermatitis

Pitolisant

Upadacitinib

Dupilumab

CC-93538

AbbVie

Celgene

Harmony Biosciences

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The primary objective of this study is to assess the long-term safety and effectiveness of pitolisant in patients with idiopathic hypersomnia (IH) who completed the Double-Blind Randomized Withdrawal Phase of study HBS-101-CL-010.

A Long-Term Safety and Effectiveness Study to Evaluate Pitolisant in Adult Patients with Idiopathic Hypersomnia

Northwestern University Feinberg School of Medicine | Feinberg School of Medicine Department of Surgery

Site insights

Work at this site?

Active trials

A Long-Term Safety and Effectiveness Study to Evaluate Pitolisant in Adult Patients with Idiopathic Hypersomnia

Trial sponsors